X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PFIZER - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PFIZER BIOCON LTD/
PFIZER
 
P/E (TTM) x 82.9 31.2 265.3% View Chart
P/BV x 7.8 5.0 157.0% View Chart
Dividend Yield % 0.2 0.7 24.4%  

Financials

 BIOCON LTD   PFIZER
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
PFIZER
Mar-16
BIOCON LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,1622,724 42.7%   
Low Rs4831,611 30.0%   
Sales per share (Unadj.) Rs194.6440.9 44.1%  
Earnings per share (Unadj.) Rs34.448.7 70.7%  
Cash flow per share (Unadj.) Rs48.375.8 63.7%  
Dividends per share (Unadj.) Rs1.0015.00 6.7%  
Dividend yield (eoy) %0.10.7 17.6%  
Book value per share (Unadj.) Rs241.9462.9 52.2%  
Shares outstanding (eoy) m200.0045.75 437.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.9 86.0%   
Avg P/E ratio x23.944.5 53.7%  
P/CF ratio (eoy) x17.028.6 59.6%  
Price / Book Value ratio x3.44.7 72.6%  
Dividend payout %2.930.8 9.4%   
Avg Mkt Cap Rs m164,44099,163 165.8%   
No. of employees `0009.22.9 319.6%   
Total wages/salary Rs m7,4702,758 270.9%   
Avg. sales/employee Rs Th4,213.96,981.7 60.4%   
Avg. wages/employee Rs Th809.0954.5 84.8%   
Avg. net profit/employee Rs Th745.2771.1 96.6%   
INCOME DATA
Net Sales Rs m38,91120,170 192.9%  
Other income Rs m1,571857 183.2%   
Total revenues Rs m40,48221,028 192.5%   
Gross profit Rs m9,7954,310 227.3%  
Depreciation Rs m2,7721,239 223.8%   
Interest Rs m2605 5,000.0%   
Profit before tax Rs m8,3343,923 212.4%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m1,6161,794 90.1%   
Profit after tax Rs m6,8812,228 308.9%  
Gross profit margin %25.221.4 117.8%  
Effective tax rate %19.445.7 42.4%   
Net profit margin %17.711.0 160.1%  
BALANCE SHEET DATA
Current assets Rs m40,47716,299 248.3%   
Current liabilities Rs m16,7837,594 221.0%   
Net working cap to sales %60.943.2 141.1%  
Current ratio x2.42.1 112.4%  
Inventory Days Days6065 91.3%  
Debtors Days Days8326 321.7%  
Net fixed assets Rs m45,0738,622 522.8%   
Share capital Rs m1,000458 218.6%   
"Free" reserves Rs m47,37720,722 228.6%   
Net worth Rs m48,37721,180 228.4%   
Long term debt Rs m21,08225 84,328.0%   
Total assets Rs m93,94229,137 322.4%  
Interest coverage x33.1755.5 4.4%   
Debt to equity ratio x0.40 36,919.6%  
Sales to assets ratio x0.40.7 59.8%   
Return on assets %7.67.7 99.2%  
Return on equity %14.210.5 135.2%  
Return on capital %12.619.0 66.4%  
Exports to sales %00.1 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs mNA3,526 0.0%   
Fx inflow Rs m12,98852 25,146.2%   
Fx outflow Rs m7,899140 5,642.9%   
Net fx Rs m5,089-88 -5,761.3%   
CASH FLOW
From Operations Rs m6,4003,436 186.2%  
From Investments Rs m-4,985-6,991 71.3%  
From Financial Activity Rs m-1,775-619 286.8%  
Net Cashflow Rs m-473-4,174 11.3%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 63.9 32.2%  
Indian inst/Mut Fund % 8.4 7.5 112.0%  
FIIs % 10.7 4.9 218.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.7 84.0%  
Shareholders   109,995 85,207 129.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - STERLING BIOTECH COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS